Why Is Abbott Stock Trending Lower?

Abbott Laboratories (ABT) has dropped by roughly 26% over the last five months, with the stock down 6% on Thursday alone.

While top-line revenue grew by 5.7% over the last year, the underlying stock performance reflects a market reassessing near-term risks against longer-term potential.

This disconnect between revenue and share price stems from a combination of acquisition costs and regulatory headwinds facing its most important product.

The Guidance Revision

The immediate catalyst for the recent selloff was a downward revision in earnings guidance. Abbott lowered its expected adjusted EPS from a range of $5.55 to $5.80 down to $5.38 to $5.58. This revision is primarily due to near-term dilution and debt requirements of the $21 billion Exact Sciences acquisition. The deal is strategically significant, positioning Abbott in the fast-growing oncology diagnostics space, though the market has focused on the short-term profitability impact.

Core Business Issues 

The more pressing concern involves the FreeStyle Libre system. This continuous glucose monitor is the company’s crown jewel, driving a meaningful portion of its MedTech growth and accounting for the bulk of the Diabetes Care division, which posted close to $8 billion in revenue last year. The device is currently under FDA scrutiny, as a manufacturing defect – which causes dangerously incorrect low glucose readings – has been linked to seven deaths and hundreds of serious injuries globally. In response, the FDA issued a Class I recall – its most severe category – and also issued a warning letter in early 2026 detailing manufacturing deficiencies at a key production facility.

While Abbott faces issues, see How Eli Lilly Stock Rises To $2,000 led by its obesity and diabetes drugs

Regulatory Uncertainty

These developments introduce a layer of uncertainty that investors should monitor closely. For a product that represents a primary growth engine, a warning letter citing quality control issues raises questions about the pace of remediation.

If the FDA finds corrective actions sufficient, the risk diminishes considerably.

If not, the company could face production delays or constraints on new product approvals – an outcome that would weigh on the growth outlook regardless of the Exact Sciences upside.

Valuation and the Road Ahead

Despite the lower share price, the stock trades at nearly 18x forward earnings. Whether that represents fair value or a premium depends heavily on how the regulatory situation resolves. Metrics like the 18.2% operating margin and 21.6% operating cash flow margin over the last year reflect strong underlying business quality, though they do not yet capture legal remediation costs or integration expenses from the acquisition.

The core question for investors is whether current headwinds are temporary or structural. Bulls point to an expanded medical device portfolio and a strong long-term position in diabetes management. Bears point to regulatory overhang and near-term earnings pressure. Neither view is unreasonable given the available information.

What to Watch

The Q2 2026 earnings call in mid-July will be an important checkpoint. Key items to track include CGM segment sales trends, any FDA updates on the warning letter response, and early signals from the Exact Sciences integration. Keep a tab on it here.

Navigating this level of single-stock risk is a professional’s game. The Trefis High Quality Portfolio is designed to grow capital while managing exactly this kind of downside volatility. Protect your portfolio with expert management. Trefis High Quality Portfolio (HQ)